AUA 2016: Studies Suggest Safety Ahead Of Lipocine's Oral Testosterone PDUFA
Executive Summary
While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.